Cladribine
Leustatin
Near Add Your Location
Accepting patients
Cladribine, Cytarabine and Venetoclax for HR-MDS
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- Phase 2
- Has results
Accepting patients
A Combination of Cladribine, Idarubicin, Cytarabine (CLIA) and Quizartinib for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS))
- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2
Accepting patients
Cytarabine Alternating with Decitabine
Phase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine in Patients With Untreated Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
- Hypomethylating Agents (HMA)
- Phase 2
Accepting patients
Chemotherapy Plus Venetoclax
Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML
- BCL-2 Inhibitor
- Kinase Inhibitor
- Tyrosine Kinase (TK) Inhibitor
- Phase 2
Accepting patients
Venetoclax as Part of Pre-Transplant Chemotherapy
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- BCL-2 Inhibitor
- Phase 2
Accepting patients
Heart Protection w/Dexrazoxane During Chemotherapy
Cardioprotection With Dexrazoxane in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS), Myeloid Blast Phase of Chronic Myeloid Leukemia (CML), Ph+ AML, and Myeloid Blast Phase of Myeloproliferative Neoplasms
- Chemotherapy
- Phase 2
Showing 1-6 of 6